IGC Pharma, Inc.
Moat Score — IGC Pharma, Inc.
Total Moat Score
4 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 1 / 5 | IGC Pharma holds a portfolio of patent applications (with a smaller number granted) around its cannabinoid-based IGC-AD1 candidate and other preclinical assets, but none covers an approved, revenue-generating drug yet, so the IP has not been validated by any regulatory or commercial outcome. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Running trials through an in-house CRO and partly funding R&D with OTC wellness product sales modestly lowers trial cost versus a typical outsourced biotech, but the company has no manufacturing, scale, or input-cost advantage versus well-capitalized competitors like Otsuka/Lundbeck or Axsome. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no approved drug and only a small branded OTC wellness products line competing against far larger consumer brands, IGC Pharma has no demonstrated pricing power in either its clinical or commercial lines today. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in IGC Pharma's business: neither its Alzheimer's drug pipeline nor its OTC wellness products become more valuable as more patients or customers use them. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | If IGC-AD1 is eventually approved for Alzheimer's-disease agitation, prescriber and caregiver switching costs could emerge once patients stabilize on a regimen, but today there is no approved product and thus no real switching cost to speak of. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The Alzheimer's-disease-agitation market is narrow and currently served by essentially one approved drug (Rexulti), which could support efficient scale for an eventual winner, but IGC Pharma is a pre-revenue-stage entrant competing against far larger, better-funded rivals for that same niche. |